209 related articles for article (PubMed ID: 11914886)
1. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
[TBL] [Abstract][Full Text] [Related]
2. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
[TBL] [Abstract][Full Text] [Related]
3. Successful diffusible brachytherapy (dBT) of a progressive low-grade astrocytoma using the locally injected peptidic vector and somatostatin analogue [90Y]-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC).
Hofer S; Eichhorn K; Freitag P; Reubi JC; Muller-Brand J; Maecke H; Merlo A
Swiss Med Wkly; 2001 Nov; 131(43-44):640-4. PubMed ID: 11835112
[TBL] [Abstract][Full Text] [Related]
4. [Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].
Otte A; Herrmann R; Mäcke HR; Müller-Brand J
Praxis (Bern 1994); 1999 Aug; 88(31-32):1263-8. PubMed ID: 10479965
[TBL] [Abstract][Full Text] [Related]
5. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.
Ferrari M; Cremonesi M; Bartolomei M; Bodei L; Chinol M; Fiorenza M; Tosi G; Paganelli G
J Nucl Med; 2006 Jan; 47(1):105-12. PubMed ID: 16391194
[TBL] [Abstract][Full Text] [Related]
6. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial.
Pless M; Waldherr C; Maecke H; Buitrago C; Herrmann R; Mueller-Brand J
Lung Cancer; 2004 Sep; 45(3):365-71. PubMed ID: 15301877
[TBL] [Abstract][Full Text] [Related]
7. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p.
Kneifel S; Cordier D; Good S; Ionescu MC; Ghaffari A; Hofer S; Kretzschmar M; Tolnay M; Apostolidis C; Waser B; Arnold M; Mueller-Brand J; Maecke HR; Reubi JC; Merlo A
Clin Cancer Res; 2006 Jun; 12(12):3843-50. PubMed ID: 16778112
[TBL] [Abstract][Full Text] [Related]
8. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
Kneifel S; Bernhardt P; Uusijärvi H; Good S; Plasswilm L; Buitrago-Téllez C; Müller-Brand J; Mäcke H; Merlo A
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1388-95. PubMed ID: 17265035
[TBL] [Abstract][Full Text] [Related]
9. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study.
Bodei L; Cremonesi M; Zoboli S; Grana C; Bartolomei M; Rocca P; Caracciolo M; Mäcke HR; Chinol M; Paganelli G
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):207-16. PubMed ID: 12552338
[TBL] [Abstract][Full Text] [Related]
10. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
Beutler D; Avoledo P; Reubi JC; Mäcke HR; Müller-Brand J; Merlo A; Kühne T
Cancer; 2005 Feb; 103(4):869-73. PubMed ID: 15641034
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 DOTATOC: first clinical results.
Otte A; Herrmann R; Heppeler A; Behe M; Jermann E; Powell P; Maecke HR; Muller J
Eur J Nucl Med; 1999 Nov; 26(11):1439-47. PubMed ID: 10552085
[TBL] [Abstract][Full Text] [Related]
12. Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results.
Paganelli G; Bartolomei M; Ferrari M; Cremonesi M; Broggi G; Maira G; Sturiale C; Grana C; Prisco G; Gatti M; Caliceti P; Chinol M
Cancer Biother Radiopharm; 2001 Jun; 16(3):227-35. PubMed ID: 11471487
[TBL] [Abstract][Full Text] [Related]
13. Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using.
Waldherr C; Schumacher T; Pless M; Crazzolara A; Maecke HR; Nitzsche EU; Haldemann A; Mueller-Brand J
Nucl Med Commun; 2001 Jun; 22(6):673-8. PubMed ID: 11403179
[TBL] [Abstract][Full Text] [Related]
14. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.
Paganelli G; Zoboli S; Cremonesi M; Bodei L; Ferrari M; Grana C; Bartolomei M; Orsi F; De Cicco C; Mäcke HR; Chinol M; de Braud F
Eur J Nucl Med; 2001 Apr; 28(4):426-34. PubMed ID: 11357492
[TBL] [Abstract][Full Text] [Related]
16. [Iridium 192 brachytherapy of supra-tentorial high grade glioma recurring in irradiated areas: technique and preliminary results of the Pitié-Salpêtrière hospital group].
Boisserie G; Cornu P; Dormont D; Sahel M; Hardiman C; Tep B; Mandin AM; Barret C; Faillot T; Delattre JY; Monjour A; Poisson M; Marsault C; Philippon J; Simon JM; Baillet F; Mazeron JJ
Bull Cancer Radiother; 1996; 83(3):144-52. PubMed ID: 8977564
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.
Ruge MI; Kickingereder P; Grau S; Dorn F; Galldiks N; Treuer H; Sturm V
Neuro Oncol; 2013 Dec; 15(12):1721-31. PubMed ID: 24046261
[TBL] [Abstract][Full Text] [Related]
18. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
[TBL] [Abstract][Full Text] [Related]
19. A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates.
Hopkins K; Chandler C; Bullimore J; Sandeman D; Coakham H; Kemshead JT
Radiother Oncol; 1995 Feb; 34(2):121-31. PubMed ID: 7597210
[TBL] [Abstract][Full Text] [Related]
20. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
